Krystal Biotech (FRA:4KB) Valuation Rank


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €313.40
GF Value €262.63
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Krystal Biotech Valuation Rank Related Terms

FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Valuation Rank:
  • GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.40
Price
€262.63
GF Value